Tandem Diabetes Care, Inc.
corporate_fare Company Profile
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for TNDM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 8/10, with 6 rated 8 or above. Recent SEC coverage for TNDM spans 10-Q, 8-K, PRE 14A, 10-K.
Recent high-impact activity:
- FDA Clears Tandem Mobi as First Tubeless AID Pump With 7-Day Wear
- Tandem Guides 2026 U.S. Sales to $730M-$745M
- Tandem 10-Q: Q3 Sales $283.7M, Net Loss $7.1M; Cash $443.1M, Debt $603.4M
- Tandem Diabetes Taps Jeannette Bankes as New President and CEO
- Tandem Diabetes Posts 10-Cent Loss Per Share in Third Quarter
Financial Snapshot
Short Interest & Short Volume
7.63 days to coverFINRA reported short interest of 16,171,009 shares in TNDM as of the October 30, 2026 settlement, a 7.2% increase from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 79.0% of TNDM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.